The big type 1 diabetes foundation JDRF this week launched a new financial vehicle to more nimbly invest in companies developing medicines or devices for type 1 diabetes.

The JDRF T1D Fund, as the vehicle is being called, launches with $42 million and aims to raise $80 million in its first two years. The new fund will focus on opportunities toward the later stages of product development. It will often take equity stakes in companies, or negotiate a share of future product royalties.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy